IMNNImunonRunning, no new patients
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jul 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 130 (planned)
- Started
- Sep 5, 2018
- Main results expected
- Jul 25, 2024
- Fully finished
- May 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS
Measured over: The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-07-25, no fading
Raw record changes
- none yet
Trial ID NCT03393884 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC